- XXII is awaiting MRTP authorization from the FDA and, once granted, the company will bring to market its VLN cigarettes.
- The company is also positioned, via its partnerships, to introduce its high THC cannabis genetics to the market.
- Currently, the company operates at a net loss, but 2021 may change this outlook.
- Their stock price is on an uptrend over the last year with gains of 460% in 6-mo, but valuation must be considered.
- I recommend a long hold strategy with the stock for a possible 25% profit.
For further details see:
22nd Century Group Positioned For Growth In Cannabis And Tobacco Markets